News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Metamark Genetics, Inc. Completes Proof-of-Concept for Protein-based Prostate Cancer Test


4/2/2012 10:31:52 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Metamark Genetics, Inc., a privately held oncology molecular diagnostics company, today announced the successful completion of proof-of-concept (POC) for its biomarker prognostic test for prostate cancer. The Metamark test is being developed to help physicians more accurately determine whether a male’s prostate cancer is slow-growing or aggressive, based on tumor tissue biopsy.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES